Merit Medical Systems, Inc. (MMSI)
| Market Cap | 3.98B |
| Revenue (ttm) | 1.52B |
| Net Income (ttm) | 128.49M |
| Shares Out | 59.65M |
| EPS (ttm) | 2.13 |
| PE Ratio | 31.34 |
| Forward PE | 16.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 736,173 |
| Open | 68.32 |
| Previous Close | 67.43 |
| Day's Range | 65.96 - 68.65 |
| 52-Week Range | 65.96 - 100.19 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 98.88 (+48.16%) |
| Earnings Date | Apr 30, 2026 |
About MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology produc... [Read more]
Financial Performance
In 2025, Merit Medical Systems's revenue was $1.52 billion, an increase of 11.75% compared to the previous year's $1.36 billion. Earnings were $128.49 million, an increase of 6.76%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for MMSI stock is "Strong Buy." The 12-month stock price target is $98.88, which is an increase of 48.16% from the latest price.
News
Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain
Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/ -- Me...
Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent
New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures...
Merit Medical Systems Earnings Call Transcript: Q4 2025
Q4 and full year 2025 results exceeded guidance, with double-digit revenue growth, record gross margin, and strong free cash flow. 2026 guidance calls for continued revenue and margin expansion, despite tariff and divestiture headwinds, and ongoing investment in growth platforms.
Merit Medical Systems Transcript: 44th Annual J.P. Morgan Healthcare Conference
New leadership is driving a smooth transition with a continued focus on customer-centric innovation and disciplined M&A. Strong financial performance includes 11% revenue growth in 2025 and improved margins, with high-growth therapeutic products and strategic acquisitions fueling future expansion.
Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025
SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appo...
Merit Medical Systems Transcript: Piper Sandler 37th Annual Healthcare Conference
Leadership transition brings renewed focus on growth through 2026, with strong confidence in meeting financial targets despite tariff impacts. Wrapsody's launch is progressing well, supporting broader portfolio momentum, while M&A strategy will become more targeted and intentional.
Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-rand...
Merit Medical Systems Earnings Call Transcript: Q3 2025
Q3 2025 saw 13% revenue growth, record gross margin, and strong free cash flow, with cardiovascular outpacing expectations and endoscopy integrating recent acquisitions. Updated 2025 guidance reflects higher revenue and EPS, while tariff and regulatory risks persist.
PENTAX Medical Announces Sale of C2 CryoBalloon™ Product Line to Merit Medical Systems through Asset Purchase Agreement
Transaction supports PENTAX Medical's strategic focus on core flexible reusable endoscopy MONTVALE, N.J. , Oct. 15, 2025 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group and a global leader in...
Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025
SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will rele...
Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology
SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care
Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis
Expanded indication provides patients with knee osteoarthritis the benefits of Embosphere's consistent, predictable, and effective clinical results. Expanded indication provides patients with knee ost...
First Patient Enrolled in Merit Medical's WRAPSODY (WRAP) North America Registry
SOUTH JORDAN, Utah, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today the successful enrollment of the first patie...
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion Thin-wall design with...
Merit Medical Systems Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue and margin growth above expectations, driven by strong U.S. demand, successful acquisitions, and robust execution. Guidance for 2025 was raised, though tariff and reimbursement uncertainties persist, especially for WRAPSODY CIE.
Merit Medical Names Martha Aronson as New President and Chief Executive Officer
Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (...
Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025
SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will rele...
The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now.
Stocks that aren't sensitive to economic ups and downs are a smart way to protect your portfolio.
Merit Medical Acquires Biolife Delaware, L.L.C.
SOUTH JORDAN, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C....
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosth...
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivota...
Merit Medical Systems Earnings Call Transcript: Q1 2025
Q1 2025 saw revenue and margin growth above expectations, driven by strong U.S. demand and successful integration of acquisitions. 2025 guidance was revised lower for EPS and margin due to $26.3 million in tariff-related costs, with mitigation efforts underway and robust free cash flow still expected.
Merit Medical Launches the Ventrax™ Delivery System
Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia Novel all-in-one retrograde aortic access delivery system supports streamlined treat...
Merit Medical Systems Transcript: 24th Annual Needham Virtual Healthcare Conference
WRAPSODY’s U.S. launch is progressing with strong clinical data, positive physician feedback, and reimbursement decisions expected in June. International growth is focused outside China, and recent M&A is enhancing product portfolios and salesforce efficiency.
Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025
SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will rel...